---
layout: default
title: "ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design"
---

# ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2512.20958" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2512.20958v1</a>
  <a href="https://arxiv.org/pdf/2512.20958.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2512.20958v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2512.20958v1', 'ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: R Yadunandan, Nimisha Ghosh

**åˆ†ç±»**: cs.LG, cs.AI

**å‘å¸ƒæ—¥æœŸ**: 2025-12-24

**ğŸ”— ä»£ç /é¡¹ç›®**: [GITHUB](https://github.com/YadunandanRaman/ReACT-Drug/)

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**ReACT-Drugï¼šåŸºäºååº”æ¨¡æ¿å¼•å¯¼çš„å¼ºåŒ–å­¦ä¹ è¯ç‰©è®¾è®¡**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±äºŒï¼šRLç®—æ³•ä¸æ¶æ„ (RL & Architecture)**

**å…³é”®è¯**: `è¯ç‰©è®¾è®¡` `å¼ºåŒ–å­¦ä¹ ` `ååº”æ¨¡æ¿` `è›‹ç™½ç»“æ„` `ä»å¤´è®¾è®¡`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç°æœ‰è¯ç‰©è®¾è®¡æ–¹æ³•éš¾ä»¥åœ¨å·¨å¤§çš„åŒ–å­¦ç©ºé—´ä¸­æ‰¾åˆ°æ—¢æœ‰é«˜äº²å’ŒåŠ›åˆæ˜“äºåˆæˆçš„å€™é€‰è¯ç‰©ã€‚
2. ReACT-Drugåˆ©ç”¨å¼ºåŒ–å­¦ä¹ ï¼Œç»“åˆè›‹ç™½ç»“æ„ä¿¡æ¯å’Œååº”æ¨¡æ¿ï¼Œå¼•å¯¼è¯ç‰©åˆ†å­ç”Ÿæˆè¿‡ç¨‹ã€‚
3. å®éªŒè¡¨æ˜ï¼ŒReACT-Drugç”Ÿæˆçš„è¯ç‰©å€™é€‰ç‰©å…·æœ‰è‰¯å¥½çš„ç»“åˆäº²å’ŒåŠ›ã€åˆæˆå¯åŠæ€§å’ŒåŒ–å­¦æœ‰æ•ˆæ€§ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ä»å¤´è¯ç‰©è®¾è®¡æ˜¯ç°ä»£è¯ç‰©å¼€å‘çš„å…³é”®ç»„æˆéƒ¨åˆ†ï¼Œä½†å¦‚ä½•åœ¨å¹¿é˜”çš„åŒ–å­¦ç©ºé—´ä¸­æ‰¾åˆ°å…·æœ‰åˆæˆå¯åŠæ€§å’Œé«˜äº²å’ŒåŠ›çš„å€™é€‰è¯ç‰©ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ã€‚å¼ºåŒ–å­¦ä¹ (RL)é€šè¿‡å®ç°å¤šç›®æ ‡ä¼˜åŒ–å’Œæ¢ç´¢æ–°çš„åŒ–å­¦ç©ºé—´æ¥å¢å¼ºè¿™ä¸€è¿‡ç¨‹â€”â€”è¿™æ˜¯ä¼ ç»Ÿç›‘ç£å­¦ä¹ æ–¹æ³•æ‰€ç¼ºä¹çš„èƒ½åŠ›ã€‚æœ¬æ–‡ä»‹ç»äº†ä¸€ä¸ªå®Œå…¨é›†æˆã€ä¸é¶æ ‡æ— å…³çš„åˆ†å­è®¾è®¡æ¡†æ¶ReACT-Drugï¼Œè¯¥æ¡†æ¶åŸºäºå¼ºåŒ–å­¦ä¹ ã€‚ä¸éœ€è¦é’ˆå¯¹ç‰¹å®šé¶æ ‡è¿›è¡Œå¾®è°ƒçš„æ¨¡å‹ä¸åŒï¼ŒReACT-Drugé‡‡ç”¨äº†ä¸€ç§é€šç”¨æ–¹æ³•ï¼Œåˆ©ç”¨ESM-2è›‹ç™½åµŒå…¥ä»è›‹ç™½è´¨æ•°æ®åº“(PDB)ç­‰çŸ¥è¯†åº“ä¸­è¯†åˆ«ç»™å®šé¶æ ‡çš„ç›¸ä¼¼è›‹ç™½ã€‚ç„¶åï¼Œå°†è¿™äº›è›‹ç™½è´¨å¯¹åº”çš„å·²çŸ¥è¯ç‰©é…ä½“åˆ†è§£ï¼Œä»¥åˆå§‹åŒ–åŸºäºç‰‡æ®µçš„æœç´¢ç©ºé—´ï¼Œä»è€Œä½¿agentåå‘äºç”Ÿç‰©å­¦ç›¸å…³çš„å­ç©ºé—´ã€‚å¯¹äºæ¯ä¸ªè¿™æ ·çš„ç‰‡æ®µï¼Œè¯¥æµç¨‹é‡‡ç”¨è¿‘ç«¯ç­–ç•¥ä¼˜åŒ–(PPO) agentï¼Œé€šè¿‡åŸºäºChemBERTaç¼–ç åˆ†å­çš„åŒ–å­¦æœ‰æ•ˆååº”æ¨¡æ¿çš„åŠ¨æ€åŠ¨ä½œç©ºé—´æ¥å¼•å¯¼åˆ†å­ã€‚è¿™äº§ç”Ÿäº†å…·æœ‰ç«äº‰æ€§ç»“åˆäº²å’ŒåŠ›å’Œé«˜åˆæˆå¯åŠæ€§çš„ä»å¤´è¯ç‰©å€™é€‰ç‰©ï¼ŒåŒæ—¶æ ¹æ®MOSESåŸºå‡†æµ‹è¯•ç¡®ä¿100%çš„åŒ–å­¦æœ‰æ•ˆæ€§å’Œæ–°é¢–æ€§ã€‚è¯¥æ¶æ„çªå‡ºäº†æ•´åˆç»“æ„ç”Ÿç‰©å­¦ã€æ·±åº¦è¡¨å¾å­¦ä¹ å’ŒåŒ–å­¦åˆæˆè§„åˆ™ä»¥è‡ªåŠ¨åŒ–å’ŒåŠ é€Ÿåˆç†è¯ç‰©è®¾è®¡çš„æ½œåŠ›ã€‚æ•°æ®é›†å’Œä»£ç å¯åœ¨https://github.com/YadunandanRaman/ReACT-Drug/è·å–ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³ä»å¤´è¯ç‰©è®¾è®¡ä¸­ï¼Œå¦‚ä½•åœ¨å·¨å¤§çš„åŒ–å­¦ç©ºé—´ä¸­é«˜æ•ˆæœç´¢å…·æœ‰é«˜äº²å’ŒåŠ›å’Œè‰¯å¥½åˆæˆå¯åŠæ€§çš„è¯ç‰©åˆ†å­çš„é—®é¢˜ã€‚ç°æœ‰æ–¹æ³•ï¼Œå¦‚åŸºäºè§„åˆ™æˆ–ç‰‡æ®µæ‹¼æ¥çš„æ–¹æ³•ï¼Œéš¾ä»¥ä¿è¯ç”Ÿæˆåˆ†å­çš„åŒ–å­¦æœ‰æ•ˆæ€§å’Œæ–°é¢–æ€§ã€‚è€Œä¼ ç»Ÿçš„ç›‘ç£å­¦ä¹ æ–¹æ³•ç¼ºä¹æ¢ç´¢æ–°åŒ–å­¦ç©ºé—´çš„èƒ½åŠ›ï¼Œä¸”éœ€è¦å¤§é‡ç‰¹å®šé¶æ ‡çš„æ•°æ®è¿›è¡Œè®­ç»ƒã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒæ€è·¯æ˜¯åˆ©ç”¨å¼ºåŒ–å­¦ä¹ ï¼Œé€šè¿‡å¥–åŠ±å‡½æ•°å¼•å¯¼agentç”Ÿæˆå…·æœ‰æœŸæœ›æ€§è´¨çš„åˆ†å­ã€‚åŒæ—¶ï¼Œåˆ©ç”¨å·²çŸ¥çš„è›‹ç™½ç»“æ„ä¿¡æ¯å’Œååº”æ¨¡æ¿ï¼Œç¼©å°æœç´¢ç©ºé—´ï¼Œæé«˜ç”Ÿæˆæ•ˆç‡å’Œåˆ†å­è´¨é‡ã€‚é€šè¿‡å°†è¯ç‰©è®¾è®¡è¿‡ç¨‹å»ºæ¨¡ä¸ºä¸€ä¸ªåºåˆ—å†³ç­–é—®é¢˜ï¼Œagentå¯ä»¥é€æ­¥æ„å»ºåˆ†å­ï¼Œå¹¶æ ¹æ®å¥–åŠ±ä¿¡å·è¿›è¡Œä¼˜åŒ–ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šReACT-Drugæ¡†æ¶åŒ…å«ä»¥ä¸‹ä¸»è¦æ¨¡å—ï¼š1) **è›‹ç™½ç›¸ä¼¼æ€§æœç´¢**ï¼šåˆ©ç”¨ESM-2è›‹ç™½åµŒå…¥ï¼Œä»PDBç­‰æ•°æ®åº“ä¸­æ‰¾åˆ°ä¸ç›®æ ‡è›‹ç™½ç›¸ä¼¼çš„è›‹ç™½ã€‚2) **é…ä½“ç‰‡æ®µæå–**ï¼šä»ç›¸ä¼¼è›‹ç™½çš„å·²çŸ¥é…ä½“ä¸­æå–ç‰‡æ®µï¼Œä½œä¸ºåˆå§‹æœç´¢ç©ºé—´ã€‚3) **å¼ºåŒ–å­¦ä¹ Agent**ï¼šä½¿ç”¨PPOç®—æ³•è®­ç»ƒagentï¼Œé€šè¿‡ChemBERTaç¼–ç åˆ†å­çŠ¶æ€ï¼Œå¹¶æ ¹æ®ååº”æ¨¡æ¿é€‰æ‹©åŠ¨ä½œã€‚4) **å¥–åŠ±å‡½æ•°**ï¼šè®¾è®¡å¥–åŠ±å‡½æ•°ï¼Œé¼“åŠ±ç”Ÿæˆå…·æœ‰é«˜äº²å’ŒåŠ›ã€è‰¯å¥½åˆæˆå¯åŠæ€§å’ŒåŒ–å­¦æœ‰æ•ˆæ€§çš„åˆ†å­ã€‚

**å…³é”®åˆ›æ–°**ï¼šè¯¥æ–¹æ³•çš„ä¸»è¦åˆ›æ–°åœ¨äºï¼š1) **ååº”æ¨¡æ¿å¼•å¯¼**ï¼šä½¿ç”¨ååº”æ¨¡æ¿ä½œä¸ºåŠ¨ä½œç©ºé—´ï¼Œä¿è¯ç”Ÿæˆåˆ†å­çš„åŒ–å­¦æœ‰æ•ˆæ€§ã€‚2) **è›‹ç™½ç»“æ„ä¿¡æ¯èåˆ**ï¼šåˆ©ç”¨è›‹ç™½ç›¸ä¼¼æ€§æœç´¢å’Œé…ä½“ç‰‡æ®µæå–ï¼Œå°†è›‹ç™½ç»“æ„ä¿¡æ¯èå…¥åˆ°è¯ç‰©è®¾è®¡è¿‡ç¨‹ä¸­ã€‚3) **é€šç”¨æ€§**ï¼šè¯¥æ¡†æ¶ä¸ä¾èµ–äºç‰¹å®šé¶æ ‡çš„è®­ç»ƒæ•°æ®ï¼Œå…·æœ‰è‰¯å¥½çš„é€šç”¨æ€§ã€‚

**å…³é”®è®¾è®¡**ï¼š1) **ååº”æ¨¡æ¿é€‰æ‹©**ï¼šä½¿ç”¨é¢„å®šä¹‰çš„ååº”æ¨¡æ¿åº“ï¼Œå¹¶æ ¹æ®å½“å‰åˆ†å­çš„ç»“æ„åŠ¨æ€é€‰æ‹©å¯ç”¨çš„ååº”æ¨¡æ¿ã€‚2) **å¥–åŠ±å‡½æ•°è®¾è®¡**ï¼šå¥–åŠ±å‡½æ•°ç»¼åˆè€ƒè™‘äº†åˆ†å­çš„ç»“åˆäº²å’ŒåŠ›ï¼ˆä½¿ç”¨å¯¹æ¥è½¯ä»¶é¢„æµ‹ï¼‰ã€åˆæˆå¯åŠæ€§ï¼ˆä½¿ç”¨SA scoreè¯„ä¼°ï¼‰å’ŒåŒ–å­¦æœ‰æ•ˆæ€§ï¼ˆé€šè¿‡æƒ©ç½šä¸åˆç†çš„åŒ–å­¦ç»“æ„å®ç°ï¼‰ã€‚3) **PPO Agent**ï¼šä½¿ç”¨Proximal Policy Optimization (PPO) ç®—æ³•è®­ç»ƒagentï¼Œå¹³è¡¡æ¢ç´¢å’Œåˆ©ç”¨ï¼Œæé«˜è®­ç»ƒæ•ˆç‡å’Œç¨³å®šæ€§ã€‚

## ğŸ–¼ï¸ å…³é”®å›¾ç‰‡

<div class="paper-figures">
<figure class="paper-figure">
<img src="https://arxiv.org/html/2512.20958v1/x1.png" alt="fig_0" loading="lazy">
</figure>
<figure class="paper-figure">
<img src="https://arxiv.org/html/2512.20958v1/x2.png" alt="fig_1" loading="lazy">
</figure>
<figure class="paper-figure">
<img src="https://arxiv.org/html/2512.20958v1/x3.png" alt="fig_2" loading="lazy">
</figure>
</div>

## ğŸ“Š å®éªŒäº®ç‚¹

ReACT-Drugåœ¨ä»å¤´è¯ç‰©è®¾è®¡ä»»åŠ¡ä¸­è¡¨ç°å‡ºè‰²ï¼Œç”Ÿæˆçš„åˆ†å­å…·æœ‰ç«äº‰æ€§çš„ç»“åˆäº²å’ŒåŠ›ã€é«˜åˆæˆå¯åŠæ€§å’Œ100%çš„åŒ–å­¦æœ‰æ•ˆæ€§ã€‚ä¸ç°æœ‰æ–¹æ³•ç›¸æ¯”ï¼ŒReACT-Drugæ— éœ€é’ˆå¯¹ç‰¹å®šé¶æ ‡è¿›è¡Œå¾®è°ƒï¼Œå…·æœ‰æ›´å¥½çš„é€šç”¨æ€§ã€‚è¯¥æ–¹æ³•åœ¨MOSESåŸºå‡†æµ‹è¯•ä¸­è¡¨ç°å‡ºè‰¯å¥½çš„æ–°é¢–æ€§ï¼Œè¡¨æ˜å…¶èƒ½å¤Ÿæ¢ç´¢æ–°çš„åŒ–å­¦ç©ºé—´ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

ReACT-Drugå…·æœ‰å¹¿æ³›çš„åº”ç”¨å‰æ™¯ï¼Œå¯ç”¨äºåŠ é€Ÿæ–°è¯å‘ç°è¿‡ç¨‹ï¼Œé™ä½ç ”å‘æˆæœ¬ã€‚è¯¥æ–¹æ³•å¯ä»¥ç”¨äºé’ˆå¯¹å„ç§ç–¾ç—…é¶æ ‡è®¾è®¡å€™é€‰è¯ç‰©ï¼Œå°¤å…¶æ˜¯åœ¨ç¼ºä¹è¶³å¤Ÿè®­ç»ƒæ•°æ®çš„æƒ…å†µä¸‹ã€‚æ­¤å¤–ï¼Œè¯¥æ¡†æ¶è¿˜å¯ä»¥ç”¨äºä¼˜åŒ–ç°æœ‰è¯ç‰©çš„æ€§è´¨ï¼Œä¾‹å¦‚æé«˜ç”Ÿç‰©åˆ©ç”¨åº¦æˆ–é™ä½æ¯’æ€§ã€‚æœªæ¥ï¼ŒReACT-Drugå¯ä»¥ä¸å…¶ä»–è®¡ç®—æ–¹æ³•ï¼ˆå¦‚åˆ†å­åŠ¨åŠ›å­¦æ¨¡æ‹Ÿï¼‰ç›¸ç»“åˆï¼Œè¿›ä¸€æ­¥æé«˜è¯ç‰©è®¾è®¡çš„å‡†ç¡®æ€§å’Œæ•ˆç‡ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> De novo drug design is a crucial component of modern drug development, yet navigating the vast chemical space to find synthetically accessible, high-affinity candidates remains a significant challenge. Reinforcement Learning (RL) enhances this process by enabling multi-objective optimization and exploration of novel chemical space - capabilities that traditional supervised learning methods lack. In this work, we introduce \textbf{ReACT-Drug}, a fully integrated, target-agnostic molecular design framework based on Reinforcement Learning. Unlike models requiring target-specific fine-tuning, ReACT-Drug utilizes a generalist approach by leveraging ESM-2 protein embeddings to identify similar proteins for a given target from a knowledge base such as Protein Data Base (PDB). Thereafter, the known drug ligands corresponding to such proteins are decomposed to initialize a fragment-based search space, biasing the agent towards biologically relevant subspaces. For each such fragment, the pipeline employs a Proximal Policy Optimization (PPO) agent guiding a ChemBERTa-encoded molecule through a dynamic action space of chemically valid, reaction-template-based transformations. This results in the generation of \textit{de novo} drug candidates with competitive binding affinities and high synthetic accessibility, while ensuring 100\% chemical validity and novelty as per MOSES benchmarking. This architecture highlights the potential of integrating structural biology, deep representation learning, and chemical synthesis rules to automate and accelerate rational drug design. The dataset and code are available at https://github.com/YadunandanRaman/ReACT-Drug/.

